Minerva Neurosciences, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 89.7K | $540.44K | 0.00% | Trimmed-39.9% | 2026-03-31 |
| StateStreet | passive | 56.3K | $339.50K | 0.00% | Added+134.6% | 2026-03-31 |
| TwoSigma | quant | 21.4K | $128.90K | 0.00% | Trimmed-4.0% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-05 | -0.13 | -0.17 | -30.77% |
| 2026-03-11 | -0.30 | -25.51 | -8403.33% |
| 2025-11-05 | -0.35 | -0.36 | -2.86% |
| 2025-08-14 | -0.90 | -0.43 | +52.22% |
| 2025-08-05 | -0.90 | — | — |
| 2025-05-13 | -1.07 | -0.50 | +53.27% |
| 2025-02-25 | -1.05 | -0.56 | +46.67% |
| 2024-11-05 | -1.01 | 2.97 | +394.06% |
| 2024-08-06 | -0.97 | -1.09 | -12.37% |
| 2024-05-01 | -1.20 | -1.13 | +5.83% |
| 2023-11-06 | -0.77 | -1.03 | -33.77% |
| 2023-08-01 | -0.44 | -1.12 | -154.55% |
| 2023-05-15 | -1.63 | -1.31 | +19.63% |
| 2023-03-08 | -0.91 | -1.26 | -38.46% |
| 2022-11-09 | -1.41 | -1.29 | +8.29% |
| 2022-08-09 | -1.68 | -1.63 | +2.98% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NERV | -19.11% | -28.43% | +22.14% | +218.83% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -22.08% | -23.79% | +25.58% | +206.14% |